|
 |
| home > ebr > spring 2003 > the development of parp inhibitors to treat cancer and other diseases |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| There is currently much debate in the pharmaceutical industry regarding the future of cancer treatment. Only time will tell if research into anti-angiogenesis, vaccines, monoclonal antibodies and myriad signalling pathways, among other therapeutic strategies, will provide returns on investment and significantly improve the treatment of cancer. At the same time, the knowledge gained from current cancer research and targeted drug discovery programmes must be viewed in light of the opportunities that it may offer for treating other important human diseases. It is important to realise that vast libraries of compounds are generated during the course of the cancer drug discovery process and many of these may have uses in disease areas that do not strategically fit with the goals and focus of the developer. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Global Clinical Outsourcing Partnerships
26-27 March 2009, Mariott Hotel, Brussels
This Jacob Fleming event is designed to promote direct business. It features a two-day educational session with case studies, presentations and interactive sessions. This forum offers networking and the forging of new business partnerships in a unique business-driven environment.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
